Global burden of HBV/HCV-related liver diseases, 1990–2021, and projections to 2050: A global burden of disease study 2021

Despite the availability of measures to control hepatitis B virus (HBV)- and hepatitis C virus (HCV)-related diseases, achieving elimination remains a substantial challenge. Effective action demands accurate assessment of the present and anticipation of the future. We utilized data from the Global Burden of Disease Study (GBD) 2021 to estimate the global burden of HBV- and HCV-related diseases for 204 countries and territories from 1990 to 2021. We defined HBV/HCV-related liver disease to include chronic hepatitis B, chronic hepatitis C, and cirrhosis attributable to chronic HBV or HCV. The burden was assessed using the age-standardized prevalence rate (ASPR), age-standardized mortality rate (ASMR), and age-standardized DALY rate (ASDR), stratified by region, age, sex, and Socio-demographic Index (SDI). GBD estimates were reported with 95% uncertainty intervals (UIs); 1990 to 2021 percentage changes were calculated from point estimates. Forecasting analysis was conducted using the GBD 2021 forecast framework, supplemented by Das Gupta decomposition analysis. From 1990 to 2021, the global ASMRs of HBV- and HCV-related cirrhosis declined by 41.51% and 31.47%, respectively, while liver cancer-related ASMR showed divergent changes (HBV: -16.40%; HCV: +2.35%). ASDRs also declined across both cirrhosis and liver cancer (HBV: -42.07%, -22.34%; HCV: -29.34%, -8.24%). Regionally, the highest ASMRs for chronic hepatitis B and C including cirrhosis in 2021 were observed in Eastern Sub-Saharan Africa (14.51 per 1,00,000) and Central Sub-Saharan Africa (13.92 per 1,00,000), respectively. The burden of both viruses was generally higher in men. Age-specific mortality rates were highest in older age groups across HBV- and HCV-related liver diseases. By the late 2030s, the mortality burden of chronic hepatitis C is projected to surpass that of chronic hepatitis B, amid a slowing annual decline in the ASMR of chronic hepatitis C (-1.21% to -0.24%). Although the overall burden of HBV- and HCV-related liver diseases may decrease or stabilize, sustained progress hinges on equitable access to vaccination, optimized antiviral therapies, and a renewed global focus on HCV as its relative impact grows. Achieving meaningful reductions across SDI contexts will require not only scientific advances but also strategic efforts to improve affordability and distribution, supported by the political will to implement change.

Authors

Institutions

Publication Details

Journal
Medicine
Published
2026-11-20
DOI
https://doi.org/10.1097/md.0000000000051529
Primary Topic
Hepatitis B Virus Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Global burden of HBV/HCV-related liver diseases, 1990–2021, and projections to 2050: A global burden of disease study 2021

Chaemin Lee, Selin Woo, Dong Keon Yon, Chae Eun Lee et al.
6 links
Medicine
Hepatitis B Virus Studies
article

Global burden of HBV/HCV-related liver diseases, 1990–2021, and projections to 2050: A global burden of disease study 2021

Chaemin Lee, Selin Woo, Dong Keon Yon, Chae Eun Lee, Seung Ha Hwang, Jaehyeong Cho
article en

Abstract

Despite the availability of measures to control hepatitis B virus (HBV)- and hepatitis C virus (HCV)-related diseases, achieving elimination remains a substantial challenge. Effective action demands accurate assessment of the present and anticipation of the future. We utilized data from the Global Burden of Disease Study (GBD) 2021 to estimate the global burden of HBV- and HCV-related diseases for 204 countries and territories from 1990 to 2021. We defined HBV/HCV-related liver disease to include chronic hepatitis B, chronic hepatitis C, and cirrhosis attributable to chronic HBV or HCV. The burden was assessed using the age-standardized prevalence rate (ASPR), age-standardized mortality rate (ASMR), and age-standardized DALY rate (ASDR), stratified by region, age, sex, and Socio-demographic Index (SDI). GBD estimates were reported with 95% uncertainty intervals (UIs); 1990 to 2021 percentage changes were calculated from point estimates. Forecasting analysis was conducted using the GBD 2021 forecast framework, supplemented by Das Gupta decomposition analysis. From 1990 to 2021, the global ASMRs of HBV- and HCV-related cirrhosis declined by 41.51% and 31.47%, respectively, while liver cancer-related ASMR showed divergent changes (HBV: -16.40%; HCV: +2.35%). ASDRs also declined across both cirrhosis and liver cancer (HBV: -42.07%, -22.34%; HCV: -29.34%, -8.24%). Regionally, the highest ASMRs for chronic hepatitis B and C including cirrhosis in 2021 were observed in Eastern Sub-Saharan Africa (14.51 per 1,00,000) and Central Sub-Saharan Africa (13.92 per 1,00,000), respectively. The burden of both viruses was generally higher in men. Age-specific mortality rates were highest in older age groups across HBV- and HCV-related liver diseases. By the late 2030s, the mortality burden of chronic hepatitis C is projected to surpass that of chronic hepatitis B, amid a slowing annual decline in the ASMR of chronic hepatitis C (-1.21% to -0.24%). Although the overall burden of HBV- and HCV-related liver diseases may decrease or stabilize, sustained progress hinges on equitable access to vaccination, optimized antiviral therapies, and a renewed global focus on HCV as its relative impact grows. Achieving meaningful reductions across SDI contexts will require not only scientific advances but also strategic efforts to improve affordability and distribution, supported by the political will to implement change.

MedicineVol. 105(47)
Ewha Womans University (KR), Kyung Hee University (KR), Kyung Hee University Medical Center (KR), Ewha Womans University Medical Center (KR), CHA University (KR), Catholic University of Korea (KR)
Good health and well-being
Hepatitis B Virus Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon